Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Somatostatin (SST)-GABAergic Interneuron Therapy for Alzheimer's Disease with ApoE4

Award Number: R44AG060873
ORGANIZATION: NATIONAL INSTITUTE ON AGING
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/15/2019
PERIOD OF PERFORMANCE END DATE: 08/31/2021

Group Awards By:

View Award Description

Somatostatin (SST)-GABAergic Interneuron Therapy for Alzheimer's Disease with ApoE4 - PROJECT SUMMARY (FAST-TRACK APPLICATION) Alzheimer’s disease (AD) is a neurodegenerative disorder affecting over 5.4 million individuals in the United States alone. Carriers of apolipoprotein (apo) E4, one of the three apoE isoforms (apoE2, apoE3, apoE4), are associated with 60–80% of all AD cases, making apoE4 the major genetic risk factor for AD. As a complex disease that causes early damage to the hippocampus, a brain region essential for cognition, AD presents unique challenges for developing traditional therapies. To date, all efforts to develop therapies that target specific AD-related pathways have failed in human trials of late-stage AD. As a result, an emerging consensus in the field is that treatment of patients with mild or moderate AD with current drugs comes too late, likely due to significant neuronal loss in the brain, especially in the hippocampus. In this regard, induced pluripotent stem cells (iPSCs) provide a way to generate human neurons or their progenitors for cell-replacement therapy. However, currently limited iPSC-based therapeutic approaches under development for potential AD treatment do not consider apoE4’s impact, which could lead to clinical failure due to patient heterogeneity and/or apoE4’s detrimental effects. By using apoE4 allelic expression to stratify patients, we will be able to create a defined patient population (apoE4-positive AD patients) for testing a matched disease-modifying treatment [human iPSC-derived somatostatin (SST)-positive GABAergic interneurons with an apoE3/3 genotype]. This proposal builds on five novel findings from our recent studies in animal models of AD and in human iPSC-derived neurons. First, apoE4 causes SST-GABAergic interneuron loss in the hippocampal hilus, which correlates with the impairment of hippocampal network activity and the extent of learning and memory deficits. Second, apoE4 causes the selective death of human iPSC–derived SST-GABAergic interneurons in culture. Third, the detrimental effect of apoE4 on SST-GABAergic interneurons is cell autonomous. Fourth, transplantation of mouse GABAergic interneuron progenitors into the hippocampal hilus restores normal learning and memory in aged apoE4 knock-in (apoE4-KI) mice without or with Aβ accumulation. Fifth, transplantation of human iPSC- derived GABAergic interneuron progenitors into the hippocampal hilus restores normal learning and memory in aged apoE4-KI mice. The goals of this proposal are 1) to develop and optimize a protocol for the robust derivation of SST-GABAergic interneurons from human iPSCs with an apoE3/3 genotype, 2) to determine the desired dose and test the safety and efficacy of transplanting human iPSC-derived SST-GABAergic interneurons into the hippocampal hilus to restore normal learning and memory in aged apoE4-KI mice, and 3) to test the safety and efficacy of transplanting human iPSC-derived SST-GABAergic interneurons into the hippocampal hilus to restore normal learning and memory in apoE4-KI mice expressing human amyloid precursor protein (APP) with mutations that cause familial AD (FAD) (hAPPFAD).


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2022 ( Subtotal = $0 )
2022	2020	GABAERON INC	1650 OWENS ST	SAN FRANCISCO	CA	94158	SAN FRANCISCO	USA	Aging Research	000	3	1/27/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2020 ( Subtotal = $948,584 )
2020	2020	GABAERON, INC.	1650 OWENS ST	SAN FRANCISCO	CA	94158	SAN FRANCISCO	USA	Aging Research	000	3	8/20/2020	NON-COMPETING CONTINUATION	$948,584
														Subtotal = $948,584

Issue Date FY: 2019 ( Subtotal = $982,084 )
2019	2019	GABAERON, INC.	1650 OWENS ST	SAN FRANCISCO	CA	94158	SAN FRANCISCO	USA	Aging Research	000	2	9/6/2019	EXTENSION WITH OR WITHOUT FUNDS	$982,084
														Subtotal = $982,084

Issue Date FY: 2018 ( Subtotal = $292,422 )
2018	2018	GABAERON, INC.	325 BERRY ST APT 327	SAN FRANCISCO	CA	94158	SAN FRANCISCO	USA	Aging Research	000	1	8/6/2018	NEW	$292,422
														Subtotal = $292,422

Grand Total All Awards = $2,223,090

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Somatostatin (SST)-GABAergic Interneuron Therapy for Alzheimer's Disease with ApoE4

Award Number: R44AG060873

ORGANIZATION: NATIONAL INSTITUTE ON AGING

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/15/2019

PERIOD OF PERFORMANCE END DATE: 08/31/2021

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer